Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei

Table 1 Clinicopathological characteristics of 32 pseudomyxoma peritonei patients

Characteristic	No. of patients (%)
Sex
Male	24 (75)
Female	8 (25)
Age (years), median (rang)	57.5 (34-74)
BSA (m2), median (rang)	1.69 (1.27-2.07)
KPS score, median (rang)	90 (60-100)
PCI score, median (rang)	31 (16-39)
Ca199 before chemotherapy, median (rang), U/mL	46.09 (4.68-10707.5)
CEA before chemotherapy, median (rang), ng/mL	16.63 (1.08-632.27)
Ca125 before chemotherapy, median (rang), U/mL	26.25 (5.3-146.7)
CC score
0-1	8 (25)
2-3	24 (75)
Histological diagnosis
Low-grade	12 (37.5)
High-grade	18 (56.2)
High-grade with signet ring cells	2 (6.3)
Lymph node metastasis
Yes	2 (6.3)
No	30 (93.7)
Vascular tumor thrombus
Yes	2 (6.3)
No	30 (93.7)
Nerve invasion
Yes	2 (6.3)
No	30 (93.7)
VEGF expression
Positive	19 (59.4)
Negative	3 (9.4)
Unknown	10 (31.2)
Microsatellite status
MSS	14 (43.8)
MSI-L	1 (3.1)
Unknown	17 (53.1)
Past use of bevacizumab
Yes	13 (40.6)
No	19 (59.4)
First-line chemotherapy (months), median (rang)	4.72 (0.01-34.73)

BSA: Body surface area; KPS: Karnofsky performance status; PCI: Peritoneal cancer index; CC: Completeness of cytoreduction; VEGF: Vascular endothelial growth factor; MSS: Microsatellite stability; MSI-L: Low microsatellite instability; CEA: Carcinoembryonic antigen.

Table 2 Adverse events, n (%)

Adverse events	Total	Grade 1-2	Grade 3-5
Total	24 (75.0)	20 (62.5)	5 (15.6)
Neutropenia	14 (43.8)	12 (37.5)	2 (6.3)
Thrombocytopenia	1 (3.1)	1 (3.1)	0 (0)
Anemia	16 (50.0)	12 (37.5)	4 (12.5)
Peripheral neurotoxicity	8 (25.0)	6 (18.8)	2 (6.3)
Fatigue	9 (28.1)	9 (28.1)	0 (0)
Nausea and vomiting	15 (46.9)	14 (43.8)	1 (3.1)
Liver damage	7 (21.9)	7 (21.9)	0 (0)
Renal impairment	9 (28.1)	9 (28.1)	0 (0)
Proteinuria	5 (15.6)	4 (12.5)	1 (3.1)
Hypertension	5 (15.6)	5 (15.6)	0 (0)
Allergy	1 (3.1)	1 (3.1)	0 (0)

Table 3 Analysis of influencing factors for progression-free survival

Prognostic factors	Univariate analysis				Multivariate analysis
	HR		95%CI	P value	HR	95%CI	P value
Sex (female vs male)	0.522	0.143-1.906		0.325		-	-
Age (< 60 vs ≥ 60)	0.630	0.208-1.910		0.414		-	-
Preoperative CEA (increased vs normal)	1.383	0.309-6.193		0.671	-	-	-
Preoperative CA199 (increased vs normal)	1.289	0.446-3.725		0.639
Preoperative CA125 (increased vs normal)	0.245	0.066-0.904		0.035	0.245	0.066-0.904	0.035
KPS (≥ 80 vs < 80)	0.946	0.119-7.493		0.958
CC (2-3 vs 0-1)	0.319	0.100-1.012		0.054	0.351	0.106-1.164	0.087
Pathology (high-grade with signet ring cells vs high-grade vs low-grade)	1.247	0.463-3.357		0.662
Lymph node metastasis (yes vs no)	0.044	0.000-435.823		0.506
Vascular tumor thrombus (yes vs no)	0.044	0.000-435.823		0.506
Nerve invasion (yes vs no)	0.043	0.000-196.970		0.464
VEGF expression (+ vs -)	0.764	0.157-3.712		0.739
CA199 before chemotherapy (increased vs normal)	0.764	0.266-2.197		0.618
CEA before chemotherapy (increased vs normal)	0.743	0.232-2.379		0.616
CA125 before chemotherapy (increased vs normal)	1.401	0.489-4.014		0.530

CEA: Carcinoembryonic antigen; KPS: Karnofsky performance status; CC: Completeness of cytoreduction.